Alpha-Ionone

Alpha-Ionone

SCHEMBL5591019

CC(=O)/C=C/[C@H]1C(C)=CCCC1(C)C

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.71
CYP3A4 P08684 1/20 0.71
ALOX15 P16050 1/20 0.71
TDP1 Q9NUW8 1/20 0.71
KDM4E B2RXH2 1/20 0.55
GAA P10253 1/20 0.55
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alpha-Ionone SCHEMBL112671 1.00 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15TDP1KDM4E
Alpha-Ionone SCHEMBL5591022 1.00 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15TDP1KDM4E
Alpha-Ionone SCHEMBL5590917 1.00 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15TDP1KDM4E
Alpha-Ionone SCHEMBL5590918 1.00 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15TDP1KDM4E
Alpha-Ionone SCHEMBL112670 1.00 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15TDP1KDM4E
Alpha-Ionone SCHEMBL901102 1.00 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15TDP1KDM4E
Alpha-Ionone SCHEMBL19816175 0.98 ALDH1A1 (0.69) ALDH1A1CYP3A4ALOX15TDP1KDM4E
SCHEMBL954796 0.87 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15TDP1KDM4E
SCHEMBL14566205 0.87 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15TDP1KDM4E
SCHEMBL954794 0.87 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4519404-A1 METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN Firmenich SA (CH) 2025-03-12 EP claimed
WO-2023247604-A1 METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN FIRMENICH SA (CH) 2023-12-28 WO claimed
EP-4161476-A1 COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF SWEAT MALODOR Firmenich SA (CH) 2023-04-12 EP claimed
WO-2022084548-A1 COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF SWEAT MALODOR FIRMENICH SA (CH) 2022-04-28 WO claimed
US-20160207765-A1 HYDROGEN GENERATOR, AND HYDROGEN GENERATION CONTAINER TAKEHARA TAKASHI (JP) 2016-07-21 US claimed
EP-4661689-A1 MICROPARTICLES CONTAINING ALGAL PROTEINS AND USES THEREOF Firmenich SA (CH) 2025-12-17 EP disclosed
EP-4633790-A1 POLYAMIDE-BASED MICROCAPSULES Firmenich SA (CH) 2025-10-22 EP disclosed
EP-4633791-A1 PROTEIN-BASED MICROCAPSULES Firmenich SA (CH) 2025-10-22 EP disclosed
WO-2024200171-A1 MICROPARTICLES CONTAINING ALGAL PROTEINS AND USES THEREOF FIRMENICH SA (CH) 2024-10-03 WO disclosed
CN-118294603-A Research method for interaction of key chiral compounds in Longjing tea 上海应用技术大学 2024-07-05 CN disclosed
WO-2024126450-A1 PROTEIN-BASED MICROCAPSULES FIRMENICH SA (CH) 2024-06-20 WO disclosed
EP-4376996-A1 PLANT PROTEIN-BASED MICROCAPSULES Firmenich SA (CH) 2024-06-05 EP disclosed
US-8053592-B2 Method for producing optically active α-ionone TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-11-08 US disclosed
US-20110118500-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE a-IONONE TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-05-19 US disclosed
US-20110118500-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE a-IONONE TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-05-19 US disclosed
US-7902404-B2 Method for producing optically active α-ionone TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-03-08 US disclosed
US-7902404-B2 Method for producing optically active α-ionone TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-03-08 US disclosed
US-20090216039-A1 Method for Producing Optically Active Alpha-Ionone TAKASAGO INTERNATIONAL CORPORATION (JP) 2009-08-27 US disclosed
US-20090216039-A1 Method for Producing Optically Active Alpha-Ionone TAKASAGO INTERNATIONAL CORPORATION (JP) 2009-08-27 US disclosed
JP-2007077226-A FLAVOR AND FRAGRANCE COMPOSITION TAKASAGO INTERNATL CORP 2007-03-29 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118500-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE a-IONONE INF2, HSD17B1, AGL ALDH1A1 322/4885CYP3A4 183/4885ALOX15 257/4885
US-20090216039-A1 Method for Producing Optically Active Alpha-Ionone HSD17B1, ENO1, INF2 ALDH1A1 357/4885CYP3A4 196/4885ALOX15 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.